Lamictal and Hepatocellular damage - a phase IV clinical study of FDA data
Summary:
Hepatocellular damage is reported as a side effect among people who take Lamictal (lamotrigine), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Valproic Acid, and have Arthritis.
The phase IV clinical study analyzes which people have Hepatocellular damage when taking Lamictal. It is created by eHealthMe based on reports of 74,218 people who have side effects when taking Lamictal from the FDA, and is updated regularly.
What is Lamictal?
Lamictal has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 82,629 Lamictal users. Check the latest studies of Lamictal.
What is Hepatocellular damage?
Hepatocellular damage (liver damage) is found to be associated with 503 drugs and 610 conditions by eHealthMe. Check the latest studies of Hepatocellular damage.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
74,218 people reported to have side effects when taking Lamictal.
Among them, 65 people (0.09%) have Hepatocellular damage.

Among these 65 people:
How long have people been on Lamictal when they have Hepatocellular damage? *
- < 1 month: 50.0 %
- 1 - 6 months: 39.29 %
- 6 - 12 months: 7.14 %
- 1 - 2 years: 3.57 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Hepatocellular damage when taking Lamictal? *
- female: 56.92 %
- male: 43.08 %
What is the age of people who have Hepatocellular damage when taking Lamictal? *
- 0-1: 0.0 %
- 2-9: 1.69 %
- 10-19: 27.12 %
- 20-29: 13.56 %
- 30-39: 15.25 %
- 40-49: 5.08 %
- 50-59: 15.25 %
- 60+: 22.03 %
What are other drugs people take besides Lamictal? *
- Depakene: 7 people, 10.77%
- Valproic Acid: 7 people, 10.77%
- Fenofibrate: 5 people, 7.69%
- Acetaminophen: 5 people, 7.69%
- Theophylline: 5 people, 7.69%
- Vioxx: 5 people, 7.69%
- Clonazepam: 4 people, 6.15%
- Arava: 3 people, 4.62%
- Carbamazepine: 3 people, 4.62%
- Pravachol: 3 people, 4.62%
What are other side effects people have besides Hepatocellular damage? *
- Fever: 29 people, 44.62%
- Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 18 people, 27.69%
- Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 11 people, 16.92%
- Thrombocytopenia (decrease of platelets in blood): 9 people, 13.85%
- Face Oedema (swelling of face): 8 people, 12.31%
- Rashes (redness): 8 people, 12.31%
- Nausea And Vomiting: 7 people, 10.77%
- Eosinophilia (eosinophil count in the peripheral blood exceeds): 7 people, 10.77%
- Renal Disorder (kidney disease): 6 people, 9.23%
- Weakness: 6 people, 9.23%
What are the existing conditions these people have? *
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 7.69%
- Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 2 people, 3.08%
- Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 1.54%
- Memory Loss: 1 person, 1.54%
- Ill-Defined Disorder: 1 person, 1.54%
- Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 1.54%
- Back Pain: 1 person, 1.54%
* Approximation only. Some reports may have incomplete information.
Do you take Lamictal and have Hepatocellular damage?
- Check whether Hepatocellular damage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Lamictal:
- Lamictal (82,629 reports)
Hepatocellular damage treatments and more:
- Hepatocellular damage (10,681 reports)
How severe was Hepatocellular damage and when was it recovered:
Expand to all the drugs that have ingredients of lamotrigine:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Lamictal:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Hepatocellular damage:
- Hepatocellular damage (503 drugs)
Browse all the conditions that are associated with Hepatocellular damage:
- Hepatocellular damage (610 conditions)
Related publications that referenced our studies
- Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
- Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
- Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
- Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on lamotrigine (the active ingredients of Lamictal) and Lamictal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Tranexamic Acid and Unasyn - a second ago
- Could Rasilez cause Lipase Increased? - 7 seconds ago
- Could Advair Diskus 100/50 cause Skin Hypopigmentation? - 7 seconds ago
- Could Ranitidine Hydrochloride cause Deep Venous Thrombosis? - 15 seconds ago
- Could Dilaudid cause Polycystic Ovary Disease? - 16 seconds ago
- Could Dilaudid cause Polyfollicular Ovarian Disease? - 16 seconds ago
- Could Ramipril cause Gastrointestinal Neoplasm? - 19 seconds ago
- Could Dynacirc cause Musculoskeletal Discomfort? - 21 seconds ago
- Linagliptin and Sweating - Excessive for Men aged 60+ - 22 seconds ago
- Could Advair Diskus 100/50 cause Skin Necrosis? - 22 seconds ago